Daniel Zandberg

20PUBLICATIONS
141CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|May 08, 2026
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

|Apr 01, 2026
Systemic Treatment of Thyroid Cancer: ASCO Guideline.

Nabil F Saba, Nofisat Ismaila, Douglas Adkins

|Mar 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

Aarti Bhatia, Zhengjia Chen, Yuji Zhang

|Jan 16, 2026
Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.

Martina Chirra, Andrew Elliott, Hira Shaikh

|Nov 03, 2025
Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.

Seka Lazare, Zhuosheng Gu, Noah Earland

|Jul 11, 2025
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik

Pageof 4

Frequent Collaborators

8 joint publications

Robert L Ferris

3 joint publications

Nabil F Saba

2 joint publications

Mark W Kubik

2 joint publications

Nassim Morsli